← All trials
NCT04588129
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 21, 2020
- Primary completion
- Mar 15, 2021
- Completion date
- May 15, 2021
- First posted
- Oct 19, 2020
- Last posted
- Dec 10, 2020
- Enrollment
- 16
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- LB Pharmaceuticals Inc.Lead sponsor
- Washington University in St. LouisCollaborator
- Washington University in St. LouisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.